Scilex Holding Co
SCLX14.350USD
-0.260-1.78%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
87.93MMarket Cap
LossP/E TTM
More Details of Scilex Holding Co Company
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Scilex Holding Co Info
Ticker SymbolSCLX
Company nameScilex Holding Co
IPO dateJan 11, 2021
CEOJi (Henry H)
Number of employees115
Security typeOrdinary Share
Fiscal year-endJan 11
Address960 San Antonio Road
CityPALO ALTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94303
Phone16505164310
Websitehttps://www.scilexholding.com/
Ticker SymbolSCLX
IPO dateJan 11, 2021
CEOJi (Henry H)
Company Executives of Scilex Holding Co
Name
Name/Position
Position
Shareholding
Change
Dr. Henry H. Ji, Ph.D.
Dr. Henry H. Ji, Ph.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
19.45K
--
Dr. Jay Chun, M.D., Ph.D.
Dr. Jay Chun, M.D., Ph.D.
Independent Director
Independent Director
3.21K
--
Dr. Yue Alexander Wu, Ph.D.
Dr. Yue Alexander Wu, Ph.D.
Independent Director
Independent Director
714.00
--
Mr. Dorman Followwill
Mr. Dorman Followwill
Independent Director
Independent Director
65.00
--
Mr. Stephen Ma
Mr. Stephen Ma
Chief Financial Officer, Chief Operating Officer, Senior Vice President, Corporate Secretary, Director
Chief Financial Officer, Chief Operating Officer, Senior Vice President, Corporate Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Henry H. Ji, Ph.D.
Dr. Henry H. Ji, Ph.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
19.45K
--
Dr. Jay Chun, M.D., Ph.D.
Dr. Jay Chun, M.D., Ph.D.
Independent Director
Independent Director
3.21K
--
Dr. Yue Alexander Wu, Ph.D.
Dr. Yue Alexander Wu, Ph.D.
Independent Director
Independent Director
714.00
--
Mr. Dorman Followwill
Mr. Dorman Followwill
Independent Director
Independent Director
65.00
--
Mr. Stephen Ma
Mr. Stephen Ma
Chief Financial Officer, Chief Operating Officer, Senior Vice President, Corporate Secretary, Director
Chief Financial Officer, Chief Operating Officer, Senior Vice President, Corporate Secretary, Director
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
56.59M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SCLX Stock Acquisition JV LLC
19.22%
Armistice Capital LLC
6.82%
The Vanguard Group, Inc.
3.72%
BlackRock Institutional Trust Company, N.A.
1.28%
Geode Capital Management, L.L.C.
0.98%
Other
67.97%
Shareholders
Shareholders
Proportion
SCLX Stock Acquisition JV LLC
19.22%
Armistice Capital LLC
6.82%
The Vanguard Group, Inc.
3.72%
BlackRock Institutional Trust Company, N.A.
1.28%
Geode Capital Management, L.L.C.
0.98%
Other
67.97%
Shareholder Types
Shareholders
Proportion
Corporation
19.22%
Hedge Fund
7.23%
Investment Advisor
6.40%
Investment Advisor/Hedge Fund
1.65%
Research Firm
0.82%
Individual Investor
0.43%
Sovereign Wealth Fund
0.18%
Bank and Trust
0.01%
Other
64.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
248
651.79K
8.80%
-877.32K
2025Q2
243
2.86M
41.63%
-723.36K
2025Q1
252
1.46M
45.15%
-3.55M
2024Q4
251
112.59M
54.83%
-47.55M
2024Q3
250
97.43M
52.53%
-74.03M
2024Q2
251
103.17M
56.73%
-57.85M
2024Q1
249
91.86M
57.21%
-68.00M
2023Q4
233
89.70M
66.12%
-73.38M
2023Q3
225
92.65M
59.63%
-2.57M
2023Q2
215
84.74M
56.99%
-3.00M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SCLX Stock Acquisition JV LLC
1.46M
19.69%
--
--
Jul 31, 2025
The Vanguard Group, Inc.
294.31K
3.97%
+125.81K
+74.66%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
118.40K
1.6%
-42.67K
-26.49%
Jun 30, 2025
Geode Capital Management, L.L.C.
61.84K
0.83%
+15.84K
+34.44%
Jun 30, 2025
State Street Investment Management (US)
11.89K
0.16%
-204.98K
-94.52%
Jun 30, 2025
UBS Financial Services, Inc.
16.00K
0.22%
-4.54K
-22.09%
Jun 30, 2025
Morgan Stanley & Co. LLC
15.70K
0.21%
+6.22K
+65.59%
Jun 30, 2025
Ji (Henry H)
19.45K
0.26%
--
--
Jul 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco NASDAQ Future Gen 200 ETF
0.01%
Humankind US Stock ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0%
Global X Genomics & Biotechnology ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.01%
Humankind US Stock ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0%
Global X Genomics & Biotechnology ETF
Proportion0%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 11, 2025
Merger
35→1
Date
Type
Ratio
Apr 11, 2025
Merger
35→1
FAQs
Who are the top five shareholders of Scilex Holding Co?
The top five shareholders of Scilex Holding Co are:
SCLX Stock Acquisition JV LLC holds 1.46M shares, accounting for 19.69% of the total shares.
The Vanguard Group, Inc. holds 294.31K shares, accounting for 3.97% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 118.40K shares, accounting for 1.60% of the total shares.
Geode Capital Management, L.L.C. holds 61.84K shares, accounting for 0.83% of the total shares.
State Street Investment Management (US) holds 11.89K shares, accounting for 0.16% of the total shares.
SCLX Stock Acquisition JV LLC holds 1.46M shares, accounting for 19.69% of the total shares.
The Vanguard Group, Inc. holds 294.31K shares, accounting for 3.97% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 118.40K shares, accounting for 1.60% of the total shares.
Geode Capital Management, L.L.C. holds 61.84K shares, accounting for 0.83% of the total shares.
State Street Investment Management (US) holds 11.89K shares, accounting for 0.16% of the total shares.
What are the top three shareholder types of Scilex Holding Co?
The top three shareholder types of Scilex Holding Co are:
SCLX Stock Acquisition JV LLC
Armistice Capital LLC
The Vanguard Group, Inc.
SCLX Stock Acquisition JV LLC
Armistice Capital LLC
The Vanguard Group, Inc.
How many institutions hold shares of Scilex Holding Co (SCLX)?
As of 2025Q3, 248 institutions hold shares of Scilex Holding Co, with a combined market value of approximately 651.79K, accounting for 8.80% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -32.83%.
What is the biggest source of revenue for Scilex Holding Co?
In FY2024, the -- business generated the highest revenue for Scilex Holding Co, amounting to -- and accounting for --% of total revenue.
